Comparative Pharmacology
Head-to-head clinical analysis: FORANE versus ISOFLURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORANE versus ISOFLURANE.
FORANE vs ISOFLURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
None Documented
None Documented
Clinical Note
moderateIsoflurane + Torasemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide."
Clinical Note
moderateIsoflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid."
Clinical Note
moderateIsoflurane + Furosemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide."
Clinical Note
moderateIsoflurane + Bumetanide
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Bumetanide."